# REPRISE IV: LOTUS Edge Valve System in Intermediate Surgical Risk Subjects

Study · id `cardio:ct-nct03618095` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT03618095](<https://clinicaltrials.gov/study/NCT03618095>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT03618095

Browse, organ or system: Heart  
Browse, condition area: Valve and congenital heart disease  

## In plain language

A trial with no phase registered on ClinicalTrials.gov. The registry status is terminated. It enrolled 382 participants.

## Technical summary

Registry record NCT03618095. Non-randomized; no masking; primary purpose treatment. Start 2019-01-14 (actual); primary completion 2021-03-30 (actual). Results posted on 2022-12-27.

## Key facts

- Design: Interventional study; non-randomized; no masking; primary purpose treatment
- Phase: Not applicable
- Enrolled: 382 participants (enrolled count; ClinicalTrials.gov record NCT03618095, source copy `cardio:ctgov-nct03618095-2022-12-27`, retrieved 2026-10-26)
- Started: 2019-01-14 (actual) (ClinicalTrials.gov record NCT03618095, source copy `cardio:ctgov-nct03618095-2022-12-27`, retrieved 2026-10-26)
- Primary completion: 2021-03-30 (actual) (ClinicalTrials.gov record NCT03618095, source copy `cardio:ctgov-nct03618095-2022-12-27`, retrieved 2026-10-26)
- Completion: 2021-03-31 (actual) (ClinicalTrials.gov record NCT03618095, source copy `cardio:ctgov-nct03618095-2022-12-27`, retrieved 2026-10-26)
- Results first posted: 2022-12-27 (ClinicalTrials.gov record NCT03618095, source copy `cardio:ctgov-nct03618095-2022-12-27`, retrieved 2026-10-26)
- Countries: United States; Australia (ClinicalTrials.gov record NCT03618095, source copy `cardio:ctgov-nct03618095-2022-12-27`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "TERMINATED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct03618095-2022-12-27`, retrieved 2026-10-26)

## The registry's words

- Brief title: REPRISE IV: LOTUS Edge Valve System in Intermediate Surgical Risk Subjects
- Acronym: REPRISE IV
- Condition: Aortic Valve Stenosis
- Intervention (Device): LOTUS Edge Valve System
- Lead sponsor: Boston Scientific Corporation
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Aortic stenosis (`cardio:aortic-stenosis`)
- Registry condition terms include this condition: Heart valve disease (`cardio:heart-valve-disease`)
- Registry lists this organization as the lead sponsor: Boston Scientific (`cardio:boston-scientific`)

## Provenance

Content hash: 74b61e5d76fb03b4a739d83764c00ef96891f0bafc30a73639ef66a8c8a54a5e
Last substantive edit: 2026-10-26
Evidence last checked: Not recorded
